U
ALDX icon

UBS’s Aldeyra Therapeutics ALDX Stock Holding History

UBS’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$5K Buy
+921
New +$4.48K ﹤0.01% 9418

Other funds holding ALDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS's ALDX Position: Q3 2014 in Review

UBS opened a new position in Aldeyra Therapeutics (ALDX) in Q3 2014: 921 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #9418 among its holdings.

7 funds tracked by Wall St. Rank hold ALDX as of Q3 2014.

  • UBS held 921 shares of Aldeyra Therapeutics worth $5K as of Q3 2014.
  • Aldeyra Therapeutics was a new UBS position in Q3 2014.
  • Aldeyra Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9418 holding.
  • 7 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.